BIOCRYST PHARMACEUTICALS, INC. Expense Breakdown
No Expense Breakdown for BCRX on this site yet.
- 2026-06-30: Reportable $3.84M.
- 2025-06-30: Reportable $2.80M.
Source checked: the stored Expense Breakdown page for BCRX.
Expenses by product
Cost of sales: each quarter (3 month)
| Quarter end | Reportable |
|---|
| 2026-06-30 | $3.84M |
|---|
| 2025-06-30 | $2.80M |
|---|
General and Administrative Expense: each quarter (3 month)
| Quarter end | Reportable |
|---|
| 2026-06-30 | $20.81M |
|---|
| 2025-06-30 | $29.82M |
|---|
Income Tax Expense (Benefit): each quarter (3 month)
| Quarter end | Reportable |
|---|
| 2026-06-30 | $1.08M |
|---|
| 2025-06-30 | $1.40M |
|---|
Research And Development Expense Acquired In Process Cost: each quarter (3 month)
| Quarter end | Reportable |
|---|
| 2026-06-30 | $0.00 |
|---|
| 2025-06-30 | $0.00 |
|---|
Selling And Marketing Expense: each quarter (3 month)
| Quarter end | Reportable |
|---|
| 2026-06-30 | $33.95M |
|---|
| 2025-06-30 | $45.59M |
|---|